IP Library › Granted Patent US 12,551,459
Granted Patent B2
US 12,551,459 · App. 15/514,680 · Granted Feb 17, 2026

Combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation

Inventors: Aziz Ghahary (Vancouver, CA); Reza B. Jalili (Vancouver, CA); Ruhangiz T. Kilani (Vancouver, CA); Yunyuan Li (Vancouver, CA)
Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
A61K31/198A61K35/15A61K35/33A61K39/0005A61K2039/5154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,459
App. No.
15/514,680
Granted
Feb 17, 2026
Kind
B2
Abstract

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (TID)) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of TID or AA are also provided.

Claims (25)

1 . A method of treating type 1 diabetes (T1D) or alopecia areata (AA), in a mammal in need thereof, the method comprising:

(a) systemic administration of an antigen presenting cell (APC) to the mammal; and

(b) administration of a kynurenine to the mammal.

2 . The method of claim 1 , wherein the APC is allogenic.

3 . The method of claim 1 , wherein the APC is syngenic.

4 . The method of claim 1 , wherein the APC is a non-professional APC.

5 . The method of claim 1 , wherein APC is a professional APC.

6 . The method of claim 1 , wherein the APC and the kynurenine are co-administered.

7 . The method of claim 6 , wherein the co-administration is simultaneously.

8 . The method of claim 6 , wherein the co-administration is consecutively.

9 . The method of claim 8 , wherein the APC is administered before the kynurenine.

10 . The method of claim 8 , wherein the kynurenine is administered before the APC.

11 . The method of claim 1 , wherein the APC is administered intraperitoneally.

12 . The method of claim 1 , wherein the kynurenine is administered orally.

13 . The method of claim 1 , wherein the APC is selected from one or more of the following: fibroblasts, thymic epithelial cells, thyroid epithelial cells, glial cells, beta-cells, and endothelial cells.

14 . The method of claim 1 , wherein the APCs are fibroblast cells.

15 . The method of claim 1 , wherein the kynurenine is selected from one of or more of kynurenic acid, DL-kynurenine, L-kynurenine, D-kynurenine, and 3-hydroxy-DL-kynurenine.

16 . The method of claim 1 , wherein the mammal is a human.

17 . The method of claim 1 , wherein the mammal is a human with T1D, and wherein the method further comprises an allogenic islet transplant.

18 . The method of claim 1 , wherein the mammal is a human with T1D, the APC is a fibroblast, and the method further comprises an allogenic islet transplant.

19 . The method, according to claim 1 , wherein the method does not comprise an islet cell transplant.

20 . The method of claim 1 , wherein the kynurenine is kynurenic acid.

21 . The method of claim 1 , wherein the kynurenine is selected from one or more of DL-kynurenine, L-kynurenine, and D-kynurenine.

22 . A pharmaceutical composition for treating disease T1D or AA, comprising a kynurenine, APCs, and a pharmaceutically acceptable carrier.

23 . A commercial package comprising (a) a kynurenine; (b) APCs; and (c) instructions for the use thereof for treating T1D or AA.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA OF INVENTOR KILANI PREVIOUSLY RECORDED ON REEL 042090 FRAME 0764. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Recorded May 27, 2017
From: GHAHARY, AZIZ; JALILI, REZA B.; KILANI, RUHANGIZ T.; LI, YUNYUAN
To: THE UNIVERSITY OF BRITISH COLUMBIA
Reel/Frame 042610/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2017
From: GHAHARY, AZIZ; JALILI, REZA B.; KILANI, RUNHANGIZ T.; LI, YUNYUAN
To: THE UNIVERSITY OF BRITISH COLUMBIA
Reel/Frame 042090/0764 →
Continuity (3)
Provisional Application 62055823 · Sep 26, 2014
Provisional Application 62087156 · Dec 3, 2014
Related Publication 20170209401A1 · Jul 27, 2017
References Cited (37)
US 10874727B2 · Riley · 2020 [cited by examiner]
US 20130102496A1 · Flechtner et al. · 2013 [cited by applicant]
US 20130315904A1 · Orban · 2013 [cited by applicant]
US 20140037607A1 · Hocini et al. · 2014 [cited by applicant]
JP 2006511208A · 2006 [cited by applicant]
JP 2014111631A · 2014 [cited by applicant]
WO 2004024902A1 · 2004 [cited by applicant]
WO WO2004060369A1 · 2004 [cited by applicant]
WO WO2010041288A1 · 2010 [cited by applicant]
WO 2012007950A2 · 2012 [cited by applicant]
WO 2012007950A3 · 2012 [cited by applicant]
WO WO2013190127A1 · 2013 [cited by examiner]
Curran, T-A, et al. Immunobiology 2013;219:17-24. [cited by examiner]
Haniffa, M.A., et al. J. Immunol. 2007;179:1595-1604. [cited by examiner]
Putnam, A.L., et al. Diabetes, 2009;58:652-662. [cited by examiner]
Umetsu 1985 (J. Clin Invest. 76(1):254-260) (Year: 1985). [cited by examiner]
Alexander, A. M. et al., “Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes.” [cited by applicant]
Hosseini-Tabatabaei, A. et al., “Embedding Islet in a Liquid Scaffold Increases Islet Viability and Function.” [cited by applicant]
Jalili, R. B. et al., “Local Expression of Indoleamine 2,3 Dioxygenase in Syngeneic Fibroblasts Significantly Prolongs Survival of an Engineered Three-Dimensional Islet Allograft.” [cited by applicant]
Spano, F., Donovan, J.C., “Alopecia areata Part 1: pathogenesis, diagnosis, and prognosis.” [cited by applicant]
Forouzandeh, F., et al., “Local expression of indoleamine 2,3-dioxygenase suppresses T-cell-mediated rejection of an engineered bilayer skin substitute.” Wound Repair and Regeneration, 2010, 18: 614-623. [cited by applicant]
Belladonna, M. L., et al., “Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes.” Transplantation, 2007, 84(1S): S17-S20. [cited by applicant]
Chess, A. C., et al., “Elevations of endogenous kynurenic acid produce spatial working memory deficits.” Schizophrenia bulletin, 2007, 33(3): 797-804. [cited by applicant]
Fallarino, F., et al., “Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.” Journal of Experimental Medicine, 2009, 206(11): 2511-2526. [cited by applicant]
Fallarino, F., et al., “The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells.” The Journal of Immunology,2006,… [cited by applicant]
O'Connor, J. C., et al., “Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice.” Molecular psychiatry, 2009, 14(5): 511-522. [cited by applicant]
Platten, M., et al., “Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite.” Science, 2005, 310(5749): 850-855. [cited by applicant]
Varga, D., et al. “Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57BI/6 mice.” Frontiers in Behavioral Neuroscience,… [cited by applicant]
Alkhalifah, A., et al., “Alopecia areata update. Part I. Clinical picture, histopathology, and pathogenesis.” The American Academy of Dermatology, 2010, 62: 177-188. [cited by applicant]
Arca, E., et al., “Interferon-gamma in alopecia areata.” Eur J Dermatol., 2004, 14(1): 33-36; abstract. [cited by applicant]
Asp, L., et al., “Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts.” Journal of Inflammation, 2011, 8(25): 1-7. [cited by applicant]
Elizei, S.S., et al., “Kynurenic acid downregulates IL-17/1L-23 axis in vitro.” Mol Cell Biochem, 2017, 431: 55-65. [cited by applicant]
Leklem, J.E., et al., “Effect of oral contraceptives on urinary metabolite excretions after administration of L-tryptophan or L-kynurenine sulfate.” Metabolism, 1973, 22(12): 1499-1505; abstract. [cited by applicant]
Limat, A., et al., “Soluble factors from human hair papilla cells and dermal fibroblasts dramatically increase the clonal growth of outer root sheath cells.” Arch Dermatol Res, 1993, 285: 205-210. [cited by applicant]
Thomson, A.W., et al., “Tolerogenic dendritic cells for autoimmune disease and transplantation.” Ann Rheum Dis, 2008, 67(Suppl III): iii90-iii96. [cited by applicant]
Li, Y., et al., “Kynurenine Increases Matrix Metalloproteinase-1 and -3 Expression in Cultured Dermal Fibroblasts and Improves Scarring In Vivo.” Journal of Investigative Dermatology, 2014, 134: 643-650. [cited by applicant]
Poormasjedi-Meibod, M.-S., et al. “Anti-Scarring Properties of Different Tryptophan Derivatives.” PloS one, 2014, 9(3): e91955, pp. 1-13. [cited by applicant]